隋江东

学历:博士研究生

职称:主任医师

职务:附属肿瘤医院肿瘤放疗中心副主任

研究方向:放射肿瘤学

学术任职

美国德州大学西南医学中心放射肿瘤学联合培养博士

重庆市杰出青年科学基金获得者

重庆市高层次人才(C类)

重庆市学术技术带头人(肿瘤放射治疗学)后备人选

重庆市中青年医学高端人才



学习经历

2011-09 至 2015-06,中国人民解放军陆军军医大学,肿瘤学,博士

2008-09 至 2011-06,中国人民解放军陆军军医大学,免疫学,硕士

2003-09 至 2008-06,中国人民解放军陆军军医大学,临床医学,学士


工作经历

2025-04 至 今,重庆大学, 附属肿瘤医院,主任医师

2020-04 至 2025-03,重庆大学,附属肿瘤医院,副主任医师

2019-06 至 2020-03,重庆大学,附属肿瘤医院,主治医师

2018-09 至 2019-05,重庆市肿瘤研究所,肿瘤放射治疗中心,主治医师

2017-10 至 2018-08,重庆市肿瘤研究所,肿瘤放射治疗中心,医师

研究方向、教学课程

研究方向:主要从事头颈恶性肿瘤的放射生物学与临床转化研究。

教学课程:肿瘤学、肿瘤放射治疗学


成果


文章(*代表第一作者;#代表通讯作者)


  1. Wang Z*, He Y, Wang Y, Shu X, Long B, Zhou W#, Sui J#. Iron status and cancer risk across 14 cancers: evidence from cross-sectional analyses and a three-stage mendelian randomization. Int J Surg. 2025 Dec 3.

  2. Zhang H*, Song Y*, Xia F*, Liu Y, Zhang L, Yang J, Tu H, Long B#, Sui J#, Wang Y#. Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study. BMC Pharmacol Toxicol. 2025;26(1):61.

  3. Zhang X*, Yan J*, Lei Q*, Neo J, Tan SH, Shu X, Huang L, Long B, Xie Y, Wang F, Wang Y, Tu H, Wang C, Zhang L, Yang J, Zhang J, Liu H, Lim DWT, Chua MLK#, Sui JD#, Wang Y#. A Randomised, Multicentre, Phase II Trial of Camrelizumab with or without Metastasis-directed Stereotactic Body Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2025 Mar 15;121(4):980-990.

  4. Lei Z*, He J*, Yang H*, Zhang L, Lai T, Zhou L, Tang Z, Sui JD#, Wu YZ#. Global profiling of Transcriptome, proteome and 2-hydroxyisobutyrylome in radioresistant lung adenocarcinoma cell. BMC Genomics. 2024 Oct 3;25(1):923.

  5. Zhang L*, Yang HN*, Wang Y, Li D, Lei Z, Yang MQ, Liu YC, He J, Wu YZ#, Sui JD#. The effectiveness of targeted therapy for recurrence or metastasis adenoid cystic carcinoma: a systematic review and meta-analysis. Ann Med. 2024 Dec;56(1):2399867.

  6. Yang HN*, Lei Z, He J, Zhang L, Lai TM, Zhou L, Wang NH, Tang Z, Sui JD#, WuYZ#. Single-cell RNA sequencing reveals recruitment of the M2-like CCL8high macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapy. J Transl Med. 2024;22(1):306.

  7. Liu YC*, Zhang X*, Yang HN, Zhang L, Li D, Yang MQ, Wang NH, Wu YZ, Sui JD#, Wang Y#. Proposals for The Delineation of Neck Clinical Target Volume for Definitive Radiation Therapy in Patients with Oral/Oropharyngeal Squamous Cell Cancer Based on Lymph Node Distribution. Radiother Oncol. 2024:195:110225.

  8. Li D*, Yang LN*, Lin JY*, Wu YZ, Tang Z, Tu HL, Zhang X, Liu YC, Yang MQ, Wang NH, Sui JD#, Mai HQ#, Wang Y#. Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study. Radiother Oncol. 2023:188:109900.

  9. Li D*, Lei HK*, Shu XL, Zhang X, Tu HL, Wang F, Wang YW, Wang Y#, Sui JD#. Association of public health insurance with cancer-specific mortality risk among patients with nasopharyngeal carcinoma: a prospective cohort study in China. Front Public Health. 2023;11:1020828.

  10. Wang NH*, Zhang X*, Sui JD#, Wang Y#, Wu YZ#, Lei QQ, Tu HL, Yang LN, Liu YC, Yang MQ, Yang HN, Li D, Lei Z. Radiation-induced eosinophil increase ratio predicts patient outcomes in non-small cell lung cancer. Front Oncol. 2022. 12:999555.

  11. Sui JD*#, Tang Z*, Chen B. P. C., Huang P, Yang MQ, Wang NH, Yang HN, Tu HL, Jiang QM, Zhang J, Wang Y#, Wu YZ#. Protein phosphatase 2A-dependent mitotic hnRNPA1 dephosphorylation and TERRA formation facilitate telomere capping. Mol Cancer Res. 2022;20(4):583-595.

  12. Lei QQ*, Sui JD*, Jin F, Luo HL, Shan JJ, Tang L, Wang Y#, Wu YZ#. Impact of high-dose rate radiotherapy on B and natural killer (NK) cell polarization in peripheral blood mononuclear cells (PBMCs) via inducing non-small cell lung cancer (NSCLC)-derived exosomes. Transl Cancer Res. 2021;10(7):3538-47.

  13. Sui J*#,Zhang S, Chen B. P. C.#. DNA-dependent protein kinase in telomere maintenance and protection. Cell Mol Biol Lett. 2020; 25:2.

  14. Sui JD*, Wang Y#, Wan Y, Wu YZ. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.Drug Des Devel Ther. 2018; 8(12):1645-57.

  15. Sui J*, Lin YF, Xu K, Lee KJ, Wang D, Chen B. P. C.#. DNA-PKcs phosphorylates hnRNP-A1 to facilitate the RPA-to-POT1 switch and telomere capping after replication. Nucleic Acids Res 2015; 43(12):5971-83.

  16. Sui J*, Li M, Qian C, Wang S, Cheng Y, Chen B. P. C., Wang D#. Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1. Drug Des Devel Ther. 2014; 8:2147-60.

  17. Sui J*, Li H*, Fang Y, Liu Y, Li M, Zhong B, Yang F, Zou Q#, Wu Y#. NLRP1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in Han Chinese. Arthritis & Rheumatism. 2012; 64(3):647-54.

项目

  1. 重庆市科学技术局,重庆市杰出青年科学基金项目,CSTB2024NSCQ-JQX0025,有丝分裂灾变导致头颈鳞癌免疫放疗抵抗的机制研究,2024-07-01 至 2027-06-30,100万元,主持

  2. 国家自然科学基金委员会,面上项目,82373196,SBRT促进hnRNPA1调控CD155可变剪切阻碍抗肿瘤免疫应答的机制研究,2024-01-01 至 2027-12-31,49万元,主持

  3. 国家自然科学基金委员会,青年科学基金项目,81802740,hnRNPA1去磷酸化在肿瘤细胞中保护染色体末端的功能机制研究,2019-01-01 至 2021-12-31,22万元,主持

  4. 重庆市卫生健康委员会,科卫联合医学科研重点项目,2022ZDXM028,立体定向放疗联合PD-1单抗治疗复发或转移头颈部鳞癌的疗效和安全性研究,2022-01 至 2024-12,40万元,主持

  5. 重庆市科学技术局,重庆市自然科学基金面上项目,CSTB2023NSCQ-MSX0709,hnRNPA1介导CD155mRNA出核转运促进头颈部鳞癌Treg细胞免疫抑制功能的机制研究,2023-07-01 至 2026-06-30,10万元,主持

  6. 重庆市科学技术委员会,基础研究与前沿探索项目,cstc2018jcyjAX0741,APE1调控NLRP1和NLRP3促进肿瘤相关巨噬细胞分泌炎症介质的作用机制,2018-08 至 2021-07,15万元,主持

    获奖

    获2025年中国抗癌协会科技奖一等奖

    获2024年重庆市科技进步二等奖

    获2022年重庆市科技进步一等奖

    获2020年重庆市医学会医学科技二等奖;

    获2012年中国免疫学会“第三届中国免疫学青年学者奖”